Abstract
Presented at the Midyear Clinical Meeting.
Overall, no statistically significant differences in door-to-needle time or secondary outcomes between alteplase and tenecteplase groups was identified. This could relate to time in imaging and patient evaluation. Patients treated with tenecteplase showed greater bleeding risk versus alteplase, though these results were not statistically significant when accounting for baseline age in an exploratory regression. Patients who received tenecteplase were slightly older, on average.
Document Type
Poster
Publication Date
2025
Recommended Citation
Beckett, Robert D. PharmD, "One bolus, many benefits: implementing tenecteplase for acute ischemic stroke" (2025). Parkview Pharmacy Department. 108.
https://researchrepository.parkviewhealth.org/pharma/108